(EMAILWIRE.COM, April 27, 2018 ) The global NGS-based RNA-seq market is projected to reach USD 2.65 Billion by 2022 from USD 1.05 Billion in 2017, at a CAGR of 20.2% during the forecast period. The advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-Seq grants, increasing number of research activities, and rapid growth in precision medicine are the key factors driving the growth of the market. On the other hand, lack of skilled professionals and standardization concerns of RNA-seq in diagnostic testing are some of the key factors limiting the growth of the market. The increasing applications of RNA-seq in research are expected to provide a wide range of growth opportunities for players in the market. Storage and interpretation of sequencing data and analysis of RNA-seq data for novel transcripts are expected to challenge market growth.

Explore More Information about report @ https://www.researchcosmos.com/reports/global-ngs-based-rna-seq-market-analysis-and-forecast-to-2022-growth-opportunity-assessment/6815340

This report broadly segments the NGS based RNA-Seq market into products & services, technology, application, and end user. On the basis of product and service, the NGS market is categorized into sample preparation, sequencing platforms & consumables, sequencing services, and data analysis, storage, & management. In 2016, the sequencing platforms and consumables segment accounted for the largest share of the market.

On the basis of technology, the market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. In 2016, the SBS technology accounted for the largest share of the market, majorly due to the development of new and advanced NGS platforms, the increasing demand for Illumina’s systems (including the HiSeq series and MiSeq), and the growing demand for NextSeq and HiSeq X Ten.

Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, small RNA sequencing, expression profiling analysis, and variant calling & transcriptome epigenetics. The expression profiling analysis segment accounted for the major share of the market and expected to register the highest growth during the forecast period.

On the basis of end user, the market is segmented into research centers and academic & government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. Among these end users, the hospitals and clinics segment is expected to register the highest CAGR due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. For instance, in February 2016, Thermo Fisher Scientific and Children's Hospital Los Angeles (CHLA, U.S.) collaborated to develop a targeted RNA & DNA sequencing-based research gene-panel specifically for pediatric cancer.

Request free sample @ https://www.researchcosmos.com/request/6815340

This report covers the NGS market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Of the four geographic regions studied in the report, North America is commanded the largest share of the market in 2016. However, Asia-Pacific is expected to register the highest growth rate during the forecast period, due to increasingly focus of key market players on strengthening their presence in the Asia-Pacific region. Globaly, the market growth is expected to be hindered by lack of skilled RNA-seq professionals across the globe.

The major players in the global market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N. V. (Germany), Pacific Biosciences of California, Inc. (U.S.), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg).

Illumina Inc. dominates the market through its wide range of technologically advanced and innovative platforms and associated RNA-seq products. The company adopts the strategy of product launches and company invests a significant amount of its revenue on R&D expenditure to maintain its leadership position in the market. For instance, in 2016, the company invested 21.0% of its revenue on R&D, as compared to 18.1% in 2015. The inorganic growth strategy includes strategic agreements with leading players in the market for the development of advanced technologies and strengthening of its research and commercialization capabilities. With its strong product portfolio and wide geographic presence, the company is expected to maintain its dominance in the market during the forecast period.

Check for discount @ https://www.researchcosmos.com/discount/6815340

Thermo Fisher Scientific is another leading market player that offers extensive range of NGS-based RNA-seq products such as analytical instruments, equipment, reagents and consumables, and software & services. It entered the market through the acquisition of Life Technologies in 2014. The company adopts various organic and inorganic strategies such as agreements with leading pharmaceutical companies, for the development of NGS-based oncology tests for companion diagnostics. With its strong geographic presence and robust product portfolio, the company is expected to witness rapid growth in the market.

About Us:

Research Cosmos is an aggregator of syndicated and bespoke market research, business intelligence and consulting services on gamut of sectors across the globe. We’re associated with world renowned publishers who when combined, serve hundreds of fortune listed companies and publish wide range of insightful reports which cover nook and corner of every industry vertical.

Contact Information:
Research Cosmos
Dani Rodriguez
Tel: +1 888 709 8757
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results